News & Updates

Vaccination against SARS-CoV-2 appears to lead to favourable outcomes in multiple myeloma (MM) patients who contract the coronavirus disease 2019 (COVID-19), even in the presence of negative prognostic factors, a recent study has found.

Adipose tissue radiodensity is significantly associated with the risk of death in patients with nonmetastatic colorectal cancer (CRC), independent of body mass index and changes in body weight, results of a study have shown.

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

Non-Hodgkin lymphoma (NHL), particularly follicular and mature T/NK-cell lymphomas, is more likely to develop among patients with breast cancer, a recent study has found. Moreover, such risk is greater among those who had been treated with hormone therapy.

The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.

Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.

Despite only being validated for use at diagnosis, risk stratification scores, such as the Mayo-2018 and the International Myeloma Working Group (IMWG)-2020 criteria, appear to be viable for post-diagnosis use in patients with smouldering multiple myeloma (SMM), a recent study has found.